share_log

We Think Yifeng Pharmacy Chain (SHSE:603939) Can Stay On Top Of Its Debt

We Think Yifeng Pharmacy Chain (SHSE:603939) Can Stay On Top Of Its Debt

我们认为益丰药房(沪市:603939)能够控制债务。
Simply Wall St ·  06/28 19:24

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We note that Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939) does have debt on its balance sheet. But the more important question is: how much risk is that debt creating?

由伯克希尔·哈撒韦公司的查理·芒格支持的外部基金经理李露对此毫不掩饰,他说:“最大的投资风险不是价格的波动,而是你是否会遭受永久的资本损失。”因此,很明显,当你考虑任何给定股票的风险时,你需要考虑债务,因为过多的债务会使公司陷入困境。我们注意到,益丰连锁药房有限公司(SHSE: 603939)的资产负债表上确实有债务。但更重要的问题是:这笔债务会带来多大的风险?

What Risk Does Debt Bring?

债务会带来什么风险?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.

一般而言,只有当公司无法通过筹集资金或用自己的现金流轻松还清债务时,债务才会成为真正的问题。资本主义的组成部分是 “创造性破坏” 过程,在这种过程中,倒闭的企业被银行家无情地清算。尽管这种情况并不常见,但我们经常会看到负债公司永久稀释股东,因为贷款人迫使他们以不良价格筹集资金。当然,债务的好处在于它通常代表廉价资本,尤其是当它以高回报率进行再投资的能力取代公司的稀释时。考虑公司的债务水平的第一步是同时考虑其现金和债务。

What Is Yifeng Pharmacy Chain's Debt?

益丰连锁药店的债务是多少?

The image below, which you can click on for greater detail, shows that at March 2024 Yifeng Pharmacy Chain had debt of CN¥3.22b, up from CN¥1.60b in one year. But on the other hand it also has CN¥6.98b in cash, leading to a CN¥3.76b net cash position.

您可以点击下图查看更多详情,该图片显示,截至2024年3月,益丰连锁药房的债务为32.2元人民币,高于一年内的16元人民币。但另一方面,它也有69.8元人民币的现金,净现金状况为37.6元人民币。

debt-equity-history-analysis
SHSE:603939 Debt to Equity History June 28th 2024
SHSE: 603939 2024 年 6 月 28 日债务与股权比率的历史记录

A Look At Yifeng Pharmacy Chain's Liabilities

看看益丰连锁药房的负债

We can see from the most recent balance sheet that Yifeng Pharmacy Chain had liabilities of CN¥11.1b falling due within a year, and liabilities of CN¥4.01b due beyond that. On the other hand, it had cash of CN¥6.98b and CN¥2.86b worth of receivables due within a year. So it has liabilities totalling CN¥5.26b more than its cash and near-term receivables, combined.

我们可以从最新的资产负债表中看出,益丰连锁药房在一年内到期的负债为111元人民币,在此之后到期的负债为40.1元人民币。另一方面,它有一年内到期的现金为69.8元人民币和价值28.6元人民币的应收账款。因此,它的负债总额比现金和短期应收账款的总和多出52.6元人民币。

Of course, Yifeng Pharmacy Chain has a market capitalization of CN¥29.8b, so these liabilities are probably manageable. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse. Despite its noteworthy liabilities, Yifeng Pharmacy Chain boasts net cash, so it's fair to say it does not have a heavy debt load!

当然,益丰连锁药房的市值为298元人民币,因此这些负债可能是可以控制的。话虽如此,很明显,我们应该继续监控其资产负债表,以免情况恶化。尽管负债可观,但益丰药房连锁店拥有净现金,因此可以公平地说,它没有沉重的债务负担!

The good news is that Yifeng Pharmacy Chain has increased its EBIT by 4.6% over twelve months, which should ease any concerns about debt repayment. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Yifeng Pharmacy Chain can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

好消息是,益丰连锁药房在十二个月内将其息税前利润增长了4.6%,这应该可以缓解对债务偿还的任何担忧。毫无疑问,我们从资产负债表中学到的关于债务的知识最多。但最终,该业务未来的盈利能力将决定益丰药房连锁店能否随着时间的推移加强其资产负债表。因此,如果您专注于未来,可以查看这份显示分析师利润预测的免费报告。

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Yifeng Pharmacy Chain may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the last three years, Yifeng Pharmacy Chain actually produced more free cash flow than EBIT. There's nothing better than incoming cash when it comes to staying in your lenders' good graces.

但是我们最终的考虑因素也很重要,因为公司无法用纸面利润来偿还债务;它需要冷硬现金。Yifeng Pharmacy Chain的资产负债表上可能有净现金,但看看该企业如何将其利息税前收益(EBIT)转换为自由现金流仍然很有趣,因为这将影响其对债务的需求和管理能力。在过去的三年中,益丰连锁药房产生的自由现金流实际上超过了eBIT。在保持贷款人的支持方面,没有什么比流入的现金更好的了。

Summing Up

总结

While Yifeng Pharmacy Chain does have more liabilities than liquid assets, it also has net cash of CN¥3.76b. The cherry on top was that in converted 155% of that EBIT to free cash flow, bringing in CN¥3.2b. So we don't think Yifeng Pharmacy Chain's use of debt is risky. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. These risks can be hard to spot. Every company has them, and we've spotted 1 warning sign for Yifeng Pharmacy Chain you should know about.

尽管益丰连锁药店的负债确实超过了流动资产,但其净现金也为37.6元人民币。最重要的是,它将息税前利润的155%转换为自由现金流,带来了32元人民币的收入。因此,我们认为益丰连锁药房使用债务没有风险。在分析债务水平时,资产负债表是显而易见的起点。但是,并非所有的投资风险都存在于资产负债表中,远非如此。这些风险可能很难发现。每家公司都有它们,我们发现了你应该知道的益丰连锁药房的一个警告标志。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果你有兴趣投资能够在没有债务负担的情况下增加利润的企业,请查看这份资产负债表上有净现金的成长型企业的免费清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,发送电子邮件至 editorial-team@simplywallst.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发